Gilead CEO says company's moving quickly with FDA for approval of coronavirus drug remdesivir

Gilead Sciences, the maker of the experimental coronavirus drug remdesivir, is giving investors more details. The company said it plans to expand manufacturing of the drug. It spent $50 million on remdesivir research and develeopment in the first quarter, and it's focused on making the drug accessible and affordable. Gilead Sciences CEO Daniel O'Day joins "Squawk Box" and CNBC's Meg Tirrell to discuss.